FindTrial
Sign In

Remimazolam tosilate sedative effect of arteriovenous fistulaplasty of extremities under local anesthesia in patients with chronic kidney disease stage V

Remimazolam tosilate sedative effect of arteriovenous fistulaplasty of extremities under local anesthesia in patients with chronic kidney disease stage V

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060191
Enrollment
Unknown
Registered
2022-05-21
Start date
2022-05-10
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uremia

Interventions

Infusion of remazolam group:Nil
Without infusion of remazolam group:Nil

Sponsors

First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 60 years, BMI<=24kg/m^2, ASA classification <?.

Exclusion criteria

Exclusion criteria: Patients with mental illness who have taken sedatives before surgery.

Design outcomes

Primary

MeasureTime frame
bispectral index monitoring (BIS) value of EEG;heart rate;mean blood pressure;finger oxygen saturation;Ramsay sedation score;doctor satisfaction;—

Countries

China

Contacts

Public ContactSun Zhentao
gentlesun@126.com+86 13603455483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026